echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Sanofi intends to acquire Translate Bio, a US biotechnology company, for US$3.2 billion to fill in the shortcomings of mRNA technology

    Sanofi intends to acquire Translate Bio, a US biotechnology company, for US$3.2 billion to fill in the shortcomings of mRNA technology

    • Last Update: 2021-08-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 3, Sanofi issued a statement stating that it will acquire Translate Bio, a US biotechnology company , for US$3.
    2 billion, which has been committed to the development of an mRNA new crown vaccine
    .

    It will acquire Translate Bio, a US biotechnology company, at a price of US$3.
    2 billion, which has been committed to the development of an mRNA COVID-19 vaccine
    .


    It will acquire Translate Bio, a US biotechnology company, at a price of US$3.


    In late June, the company said it would invest 2 billion euros in the technology to establish a "center of excellence" employing 400 employees in its laboratories in Marcy-L'Etoile near Cambridge, USA and Lyon, France
    .


    The messenger RNA technology produces the surface protein of the coronavirus by providing genetic instructions to human cells, thereby training the immune system to recognize the real virus


    immunity

    The manufacture of traditional vaccines is a longer process and usually involves the development of a weakened form of the pathogen
    .


    Sanofi, which originally took the traditional route, still holds a place in the huge market


    manage

    Sanofi has been cooperating with Translate Bio in Lexington, Massachusetts to develop mRNA vaccines.
    The company said it is betting on new technologies beyond the coronavirus pandemic
    .


    Sanofi CEO Paul Hudson (Paul Hudson) said in a statement: "This transaction will allow the two companies to accelerate their existing development plans.


    "This transaction will enable the two companies to accelerate their existing development plans.


    Founded in 2016, it has not yet launched any drugs on the market.


    Sanofi is trying to catch up with rivals Pfizer, BioNTech and Moderna, after their new crown vaccines are on the market to prove that mRNA can make highly effective vaccines
    .


    They took advantage of the pandemic to win the first batch of approvals for mRNA vaccines and expanded production facilities


    Sanofi's new crown vaccine work is lagging behind
    .


    Its recombinant protein vaccine developed under the promotion of GlaxoSmithKline's adjuvant is in phase 3 trials, and its plan with Translate Bio is in an earlier phase 1/2 study, and results are expected to be obtained in the third quarter


    Sanofi sold half of its 20.
    6% stake in Renewable Yuan for US$6.
    1 billion last year, creating a capital reserve fund for potential transactions
    .


    Paul Hudson took over in 2019 and developed a new strategy for Sanofi, focusing on growth areas such as oncology and rare diseases


    Focus on growth areas such as oncology and rare diseases
    .
    Focus on growth areas such as oncology and rare diseases
    .

    After Sanofi's second-quarter performance exceeded expectations, its annual revenue in 2021 is expected to increase by 12%
    .
    Driven by the company's eczema drug Dupixent (dupilumab) and its vaccine portfolio, sales for the quarter ended June 2021 "increased by double digits" to 8.
    7 billion euros (increased by 12.
    4% on CER)
    .

    Dupixent's sales increased by 56.
    6% (to 1.
    24 billion euros), driving Sanofi's professional care business by 22%
    .
    The largest share of Dupixent's sales was in the United States (947 million euros, an increase of 48.
    9%), due to the strong demand for atopic dermatitis and the continued growth of asthma and chronic sinusitis and nasal polyposis
    .
    Driven by meningitis and enhanced injections, vaccine sales increased by 16.
    2% to 1.
    02 billion euros
    .

    Despite being hit by the pandemic last year, Sanofi performed strongly in 2021.
    Since January, its share price has risen by nearly 11%, behind Pfizer's 18%, but ahead of GlaxoSmithKline's 4%
    .

    Vaccines remain the focus of the company, which is one of the largest vaccine manufacturers in the world
    .
    In order to overcome the delay caused by a dose error in an important study, Sanofi hopes to launch the new crown vaccine jointly developed with GSK before the end of the year
    .

    As competitors such as BioNTech/Pfizer and Moderna are far ahead in the new crown vaccination competition, Sanofi said that its injection of vaccines may help strengthen injections
    .
    Chief Financial Officer Jean-Baptiste Chasseloup de Chatillon said: "The potential demand for enhanced injections is growing, and the government is very interested in our new crown vaccine
    .
    "

    Last month, the company announced the launch of its first mRNA vaccine center of excellence
    .
    An annual investment of 400 million euros will address key challenges, including thermal stability and tolerability, which prevent the technology from becoming part of routine vaccination against a range of infectious diseases
    .
    The center will focus on accelerating the development and supply of next-generation vaccines
    .
    By 2025, the mRNA vaccine center of excellence is expected to develop at least 6 clinical candidate vaccines
    .

    Sanofi also highlighted several important R&D milestones and regulatory achievements in the second quarter:

    The key research conclusion of nirsevimab in the treatment of respiratory syncytial virus infection.

    The first phase of the new influenza vaccine study began
    .
    European regulatory approval of cancer treatment drugs Libtayo and Sarclisa.

    The acquisition of Tidal Therapeutics, Kiadis and Kymab was completed.

    The key research nirsevimab treatment of respiratory syncytial virus infection conclusion the treatment of respiratory syncytial virus key findings infections nirsevimab treatment of respiratory syncytial virus infection of the key findings nirsevimab
    first phase of the study began a new influenza vaccine research first phase of the new flu vaccine Started the first phase of the new influenza vaccine study.
    Started
    the European regulatory approval of the cancer treatment drugs Libtayo and Sarclisa.
    The European regulatory approval of the cancer treatment drugs Libtayo and Sarclisa.
    The European regulatory approval of the cancer treatment drugs Libtayo and Sarclisa.
    The
    completion of the acquisition of Tidal Therapeutics, Kiadis and Kymab Completed the acquisition of Tidal Therapeutics, Kiadis and Kymab.
    Completed the acquisition of Tidal Therapeutics, Kiadis and Kymab.

    Sanofi is not the only company with such ambitions
    .
    German BioNTech, which is cooperating with the US giant Pfizer to develop a coronavirus vaccine, announced in July that its goal is to start testing a malaria vaccine using mRNA breakthrough technology
    .

    Reference materials: https:// href="https://" target="_blank" rel="noopener">https:// 

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.